Henrik5000/E+ via Getty Images Israel based computational biology company Evogene ( NASDAQ: EVGN ) said on Friday it has entered into agreements with an institutional investor for the purchase and sale of 1.69M shares in a direct offering. Evogene ( EVGN ) expects gross proceeds of about $5.
5M from the offering and intends to use it for working capital and general corporate purposes. The company also announced a concurrent private placement, to issue unregistered Series A and B warrants to purchase up to 1.69M shares with an exercise price of $3.
55 per share. The closing of the direct offering is expected to occur on or about August 26th. Evogene ( EVGN ) stock was up 0.
85% during trading hours. More on Evogene Evogene Ltd. (EVGN) Q2 2024 Earnings Call Transcript Evogene to effect 1-for-10 reverse stock split Seeking Alpha’s Quant Rating on Evogene Historical earnings data for Evogene Financial information for Evogene.